FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W132816635> ?p ?o ?g. }

• W132816635 endingPage "2" @default.
• W132816635 startingPage "32" @default.
• W132816635 abstract "Single-agent activity has been observed for both docetaxel and irinotecan in several solid tumors, including non-small cell lung cancer (NSCLC). Compilation of data from phase II trials of single-agent docetaxel therapy in NSCLC yielded overall response rates of 26% and a 1-year survival rate of 52%. Furthermore, a recent study that combined radiotherapy with concurrent docetaxel treatment reported an overall response rate of 77%. The most important adverse effect of docetaxel therapy is neutropenia Phase II trials of single-agent irinotecan for NSCLC patients resulted in response rates of 15% to 31%. The main toxicities were neutropenia and diarrhea. Investigators have begun to explore the efficacy of combining docetaxel and irinotecan. The results of preclinical studies suggest that schedule and order of administration may be important. A Japanese study evaluated the combination in previously untreated patients with NSCLC, and found eight partial responses in 26 patients (32%). A recent phase I study at the Mayo Clinic showed partial responses in three of five patients who received irinotecan followed by docetaxel. In a phase I study conducted at Yale Cancer Center, escalating doses of docetaxel (25 to 40 mg/m2) were given before irinotecan (50 mg/m2) for 4 weeks followed by a 2-week rest. There was one partial response among five evaluable patients with NSCLC (one of four among patients who had received no prior chemotherapy). The results of these studies suggest that the combination of docetaxel and irinotecan shows promise in the treatment of NSCLC. Irinotecan also has been used in combination with other chemotherapeutic agents. The irinotecan/etoposide combination has been less extensively evaluated but thus far appears to be associated with considerable toxicity, particularly myelosuppression, without clear therapeutic advantage. One report of the use of the triple combination of irinotecan/cisplatin/etoposide resulted in 16 partial responses in 42 NSCLC patients (38%). Like docetaxel, irinotecan has been used effectively in conjunction with radiation therapy, with partial response rates in some studies of more than 70%." @default.
• W132816635 created "2016-06-24" @default.
• W132816635 creator A5008924495 @default.
• W132816635 creator A5023799792 @default.
• W132816635 creator A5037931237 @default.
• W132816635 creator A5041114807 @default.
• W132816635 creator A5046167489 @default.
• W132816635 creator A5048408082 @default.
• W132816635 creator A5075655484 @default.
• W132816635 creator A5088211881 @default.
• W132816635 date "1999-10-01" @default.
• W132816635 modified "2023-09-23" @default.
• W132816635 title "Docetaxel and irinotecan, alone and in combination, in the treatment of non-small cell lung cancer." @default.
• W132816635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10585007" @default.
• W132816635 hasPublicationYear "1999" @default.
• W132816635 type Work @default.
• W132816635 sameAs 132816635 @default.
• W132816635 citedByCount "6" @default.
• W132816635 crossrefType "journal-article" @default.
• W132816635 hasAuthorship W132816635A5008924495 @default.
• W132816635 hasAuthorship W132816635A5023799792 @default.
• W132816635 hasAuthorship W132816635A5037931237 @default.
• W132816635 hasAuthorship W132816635A5041114807 @default.
• W132816635 hasAuthorship W132816635A5046167489 @default.
• W132816635 hasAuthorship W132816635A5048408082 @default.
• W132816635 hasAuthorship W132816635A5075655484 @default.
• W132816635 hasAuthorship W132816635A5088211881 @default.
• W132816635 hasConcept C121608353 @default.
• W132816635 hasConcept C126322002 @default.
• W132816635 hasConcept C143998085 @default.
• W132816635 hasConcept C2776256026 @default.
• W132816635 hasConcept C2776694085 @default.
• W132816635 hasConcept C2777063308 @default.
• W132816635 hasConcept C2780259306 @default.
• W132816635 hasConcept C2781190966 @default.
• W132816635 hasConcept C526805850 @default.
• W132816635 hasConcept C71924100 @default.
• W132816635 hasConceptScore W132816635C121608353 @default.
• W132816635 hasConceptScore W132816635C126322002 @default.
• W132816635 hasConceptScore W132816635C143998085 @default.
• W132816635 hasConceptScore W132816635C2776256026 @default.
• W132816635 hasConceptScore W132816635C2776694085 @default.
• W132816635 hasConceptScore W132816635C2777063308 @default.
• W132816635 hasConceptScore W132816635C2780259306 @default.
• W132816635 hasConceptScore W132816635C2781190966 @default.
• W132816635 hasConceptScore W132816635C526805850 @default.
• W132816635 hasConceptScore W132816635C71924100 @default.
• W132816635 hasIssue "5 Suppl 16" @default.
• W132816635 hasLocation W1328166351 @default.
• W132816635 hasOpenAccess W132816635 @default.
• W132816635 hasPrimaryLocation W1328166351 @default.
• W132816635 hasRelatedWork W2273140211 @default.
• W132816635 hasRelatedWork W2347520915 @default.
• W132816635 hasRelatedWork W2351661875 @default.
• W132816635 hasRelatedWork W2362830621 @default.
• W132816635 hasRelatedWork W2383259583 @default.
• W132816635 hasRelatedWork W2392222733 @default.
• W132816635 hasRelatedWork W2403847123 @default.
• W132816635 hasRelatedWork W2591445942 @default.
• W132816635 hasRelatedWork W4253519788 @default.
• W132816635 hasRelatedWork W2001314934 @default.
• W132816635 hasVolume "26" @default.
• W132816635 isParatext "false" @default.
• W132816635 isRetracted "false" @default.
• W132816635 magId "132816635" @default.
• W132816635 workType "article" @default.